Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sam who wrote (5096)	8/6/1998 5:40:00 PM
From: Intel Trader	Read Replies (1) of 6136

FWIW, I'd agree with Peter re current mkt conditions influencing Agouron's share price. I called Claudia B. at Agouron yesterday and she confirmed an ICAAC conference about 23 September 1998 that they would be at. She also talked about an NDA for a lung cancer drug (AG3340?) that was upcoming in calendar year 2000. Further, more information about the oncology division formation would be issued about mid to late September, 1998. Lastly, more developments with Remune + Viracept are due in 6-7 months from now. I hope that this information is not too vague and is substantially correct, but it is compiled from some rather poorly written notes. We spoke for a few minutes, and the impression I got was that Agouron's investor relations people do have concern for the smaller shareholders who would include us. She seemed to be more responsive and willing to share more information than other IR sections at companies that I've contacted before. Best regards to all, it

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next